Charles River Laboratories International (NYSE:CRL) Releases FY25 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $9.10-$9.60 for the period, compared to the consensus estimate of $9.60. The company issued revenue guidance of $3.77-$3.87 billion, compared to the consensus revenue estimate of $3.87 billion. Charles River Laboratories International also updated its FY 2025 guidance to 9.100-9.600 EPS.

Analyst Ratings Changes

A number of research analysts recently weighed in on CRL shares. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. Morgan Stanley cut their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. The Goldman Sachs Group lowered their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, TD Cowen raised their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and a consensus price target of $197.64.

Charles River Laboratories International Stock Up 6.9 %

Charles River Laboratories International stock traded up $10.61 during midday trading on Wednesday, hitting $165.00. 1,734,115 shares of the company’s stock were exchanged, compared to its average volume of 1,017,311. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market cap of $8.44 billion, a PE ratio of 20.65, a P/E/G ratio of 5.91 and a beta of 1.37. The firm has a 50-day moving average of $174.59 and a two-hundred day moving average of $189.16.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year. During the same period last year, the company posted $2.46 earnings per share. As a group, analysts expect that Charles River Laboratories International will post 10.16 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).